MedTrace Logo

Periosteal Electrical Dry Needling in Knee Osteoarthritis

NCT05398601 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-07-13

No results posted yet for this study

Summary

To determine the effect of periosteal electrical dry needling as an adjuvant to MWM in knee osteoarthritis for pain management, for improvement in functional activities and for ROM (Range Of Motion)

Conditions

Interventions

OTHER

MOBILIZATION with MOVEMENT

They would be receiving conventional treatment as follow: TENS (Transcutaneous electrical nerve stimulation) applied asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold - 10 mins Hot Pack - 10 mins ULTRASOUND - 10 mins Additionally, the would receive MWM techniques for Knee 1. Medial glide 2. Medial+ Internal rotation glide 3. Lateral Glide+ Internal Rotation glide 4. Anterior glide 5. Posterior glide

OTHER

Periosteal electrical dry needling

They would be receiving conventional treatment as follow: TENS (asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold) - 10 mins HOT PACK - 10 mins ULTRASOUND - 10 mins Additionally, the would receive periosteal electrical dry needling 4 point technique for Knee Four sterile, single-use 30-gauge dry needles would be inserted into the following locations of the symptomatic knee(s) until they touch bone: 1. Medial femoral condyle 2. Lateral femoral condyle 3. Flare of the tibia 4. Head of the fibula Needles would be stimulated with 100 Hz for 30 minutes. The intensity of the stimulus would be adjusted so that it would be clearly felt but would not cause discomfort. The stimulus intensity would be adjusted periodically so that it is perceptible for the entire 30 minutes of PST.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • KINZA ANWAR, MS-OMPT · RIPHAH INTERNATIONAL UNIVERSITY,ISLAMABAD,PAKISTAN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-14
Primary Completion
2023-07-08
Completion
2023-07-10

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05398601 on ClinicalTrials.gov